SCHEMBL19865656

SCHEMBL19865656

CNC1CCCc2cc(Cl)ccc21

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TAS1R2 Q8TE23 1/20 0.46
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
PFKFB3 Q16875 1/20 0.42
F10 P00742 1/20 0.41
LMNA P02545 1/20 0.41
SRD5A1 P18405 1/20 0.40
SRD5A2 P31213 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27856212 0.90 PDPK1 (0.58) PDPK1HTR2AHTR2CHTR2BPDE4A
SCHEMBL19862554 0.84 TAS1R3 (0.44) TAS1R3TAS1R1TAS1R2HTR2AHTR2C
SCHEMBL28460491 0.80 PDPK1 (0.46) PDPK1TAS1R3TAS1R1TAS1R2LMNA
Methane SCHEMBL9715532 0.78 TAS1R3 (0.44) PDPK1TAS1R3TAS1R1TAS1R2PFKFB3
SCHEMBL16254293 0.78 TAS1R3 (0.54) TAS1R3TAS1R1TAS1R2
SCHEMBL28454727 0.78 PDPK1 (0.44) PDPK1
SCHEMBL15577013 0.77 HTR2C (0.58) TAS1R3TAS1R1TAS1R2HTR2AHTR2C
SCHEMBL18468830 0.77 HTR2C (0.58) TAS1R3TAS1R1TAS1R2HTR2AHTR2C
SCHEMBL19302170 0.77 HTR2C (0.58) TAS1R3TAS1R1TAS1R2HTR2AHTR2C
SCHEMBL31136459 0.76 PDE2A (0.49) PDPK1LMNASRD5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-11-14 US disclosed
WO-2024220917-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-24 WO disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 PDPK1 1815/4885TAS1R3 3257/4885TAS1R1 2947/4885
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 PDPK1 994/4885TAS1R3 3911/4885TAS1R1 3790/4885
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE PDE3A, PDE2A, PDE5A PDPK1 110/4885TAS1R3 4061/4885TAS1R1 3875/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 PDPK1 994/4885TAS1R3 3911/4885TAS1R1 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.